Galapagos NV (GLPG)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

€26.44

Buy

€26.52

arrow-down€-0.16 (-0.60%)

Prices updated at 16 Dec 2025, 14:03 CET

Prices minimum 15 mins delay

Prices in EUR

Galapagos NV is a clinical-stage biotechnology company. It is engaged in the discovery and development of small molecule medicines which address unmet medical conditions.

FTSE EuroFirst 300

-0.27%

Amsterdam

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Dr. Paulus Stoffels

CEO

Dr. Paulus Stoffels

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

704

Head office

Generaal De Wittelaan L11 A3

Mechelen

Belgium

2800

+32 15342900

ir@glpg.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Andrew D. Dickinson Director	-
Mr. Oleg Nodelman Director	-
Mr. Jerome Contamine Lead Independent Director	0.12m
Mr. Simon John Sturge Independent Director	0.08m
Dr. Paulus Stoffels Chairman of the Board and Chief Executive Officer	0.77m
Mr. Peter Guenter Independent Director	0.07m
Mr. Thad Allen Huston Chief Financial Officer, Chief Operating Officer and Executive Vice President	-
Dr. Susanne Schaffert, PhD Independent Director	0.07m
Dr. Linda Higgins, PhD Director	-
Dr. Elisabeth Svanberg Independent Director	0.12m
Ms. Valeria Cnossen General Counsel and Executive Vice President	-
Ms. Annelies Missotten Chief Human Resources Officer and Executive Vice President	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
FMR LLC	2,588,831
Vanguard Group Inc	1,510,155
Vanguard Total Intl Stock Idx Fund	711,521
Dimensional Fund Advisors LP	689,042
BlackRock Fund Advisors	569,182

Director dealings

Date chevron-l-regular chevron-r-regular	Action
No data

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.